PMID- 36618925
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - The effects of qishen granules for patients with chronic heart failure: A 
      multicenter randomized double-blind placebo-controlled trial.
PG  - 1017734
LID - 10.3389/fphar.2022.1017734 [doi]
LID - 1017734
AB  - Background: Despite advancements in chronic heart failure (CHF) treatment, the 
      effect often remains unsatisfactory and unstable. More effective therapies are 
      needed. Qishen granules (QSG) are a novel Chinese botanical drug effective in 
      treating CHF in animal models, but clinical evidence remains inadequate. 
      Objective: This study aims to evaluate the effects of QSG on patients with CHF. 
      Methods: We enrolled CHF patients in this 12-week, randomized, double-blind, 
      placebo-controlled trial and randomly assigned them to the QSG (twice a day, 
      6.8 g granules at once) or placebo group. The primary endpoint was a change in 
      the plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level after 
      treatment. The secondary outcome consists of the New York Heart Association 
      (NYHA) functional classification, 6-min walking distance (6MWD), TCM syndrome 
      integral scale, quality of life, and echocardiographic index. Results: A total of 
      191 patients completed the 12-week follow-up period, with 94 in the QSG group and 
      97 in the placebo group. The Qishen granules group demonstrated a considerably 
      greater reduction in NT-proBNP than the placebo group (50% vs 32% for QSG vs 
      placebo, respectively; p = 0.011). Patients who received QSG performed better in 
      the NYHA functional rank, 6MWD, TCM syndrome integral scale, and quality of life 
      (p < 0.05). The QSG group performed better in HFrEF patients regarding the 
      efficiency of NT-proBNP. There was no statistical significance in the change in 
      evaluated safety parameters, such as blood routine and biochemistry. Conclusion: 
      Based on standard treatment, Qishen granules further reduced the levels of 
      NT-proBNP when compared with placebo. Together with other outcomes, our findings 
      suggest that QSG could be used in combination therapy for CHF. Clinical Trial 
      Registration: www.clinicaltrials.gov, identifier NCT03027375. Registered 9 
      October 2017.
CI  - Copyright (c) 2022 Du, Liu, Tan, Huang, Wang, Zhao and Wang.
FAU - Du, Kangjia
AU  - Du K
AD  - Department of Chinese medicine, Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Liu, Junjie
AU  - Liu J
AD  - Department of Cardiology, Nanjing Pukou Hospital of Traditional Chinese Medicine, 
      Nanjing, China.
FAU - Tan, Nannan
AU  - Tan N
AD  - Department of Chinese medicine, Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Huang, Xinyi
AU  - Huang X
AD  - Department of Chinese medicine, Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Wang, Juan
AU  - Wang J
AD  - Department of Chinese medicine, Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Zhao, Huihui
AU  - Zhao H
AD  - Department of Chinese medicine, Beijing University of Chinese Medicine, Beijing, 
      China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Chinese medicine, Beijing University of Chinese Medicine, Beijing, 
      China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03027375
PT  - Journal Article
DEP - 20221223
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9822771
OTO - NOTNLM
OT  - NT-probnp
OT  - chronic heart failure
OT  - detoxification
OT  - qi shen granules
OT  - randomized controlled trial
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/10 06:00
MHDA- 2023/01/10 06:01
PMCR- 2022/12/23
CRDT- 2023/01/09 03:41
PHST- 2022/08/12 00:00 [received]
PHST- 2022/12/08 00:00 [accepted]
PHST- 2023/01/09 03:41 [entrez]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/10 06:01 [medline]
PHST- 2022/12/23 00:00 [pmc-release]
AID - 1017734 [pii]
AID - 10.3389/fphar.2022.1017734 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Dec 23;13:1017734. doi: 10.3389/fphar.2022.1017734. 
      eCollection 2022.